Genome-wide ChIP-seq data with a transcriptome analysis reveals the groups of genes regulated by histone demethylase LSD1 inhibition in esophageal squamous cell carcinoma cells

Expression of genes is controlled by histone modification, histone acetylation and methylation, but abnormalities of these modifications have been observed in carcinogenesis and cancer development. The effect of the lysine-specific histone demethylase 1 (LSD1) inhibitor, a demethylating enzyme of histones, is thought to be caused by controlling the expression of genes. The aim of the present study is to elucidate the efficacies of the LSD1 inhibitor on the gene expression of esophageal cancer cell lines using chromatin immunoprecipitation (ChIP)-Seq. A comprehensive analysis of gene expression changes in esophageal squamous cell carcinoma (ESCC) cell lines induced by the LSD1 inhibitor NCL1 was clarified via analysis using microarray. In addition, ChIP-seq analysis was conducted using a SimpleChIP plus Enzymatic Chromatin IP kit. NCL1 strongly suppressed the proliferation of T.Tn and TE2 cells, which are ESCC cell lines, and further induced apoptosis. According to the combinatory analysis of ChIP-seq and microarray, 17 genes were upregulated, and 16 genes were downregulated in both cell lines. The comprehensive gene expression study performed in the present study is considered to be useful for analyzing the mechanism of the antitumor effect of the LSD1 inhibitor in patients with ESCC.

[1]  A. Melnick,et al.  ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. , 2018, Cancer cell.

[2]  Daniele M. Gilkes,et al.  RhoB: Team Oncogene or Team Tumor Suppressor? , 2018, Genes.

[3]  Y. Nie,et al.  Prognostic value of an immunohistochemical signature in patients with esophageal squamous cell carcinoma undergoing radical esophagectomy , 2018, Molecular oncology.

[4]  Y. Doki,et al.  PRIMA‐1 induces p53‐mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation , 2017, Cancer science.

[5]  Jesper Lagergren,et al.  Oesophageal cancer , 2017, The Lancet.

[6]  Ming-Rong Wang,et al.  Genomic and Epigenomic Aberrations in Esophageal Squamous Cell Carcinoma and Implications for Patients. , 2017, Gastroenterology.

[7]  Xianglin Yuan,et al.  Thrombospondin-1 is a multifaceted player in tumor progression. , 2017, Oncotarget.

[8]  You-Lin Qiao,et al.  Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China , 2017, Cancer biology & medicine.

[9]  L. Rushworth,et al.  Dual-specificity phosphatase 5 controls the localized inhibition, propagation, and transforming potential of ERK signaling , 2017, Proceedings of the National Academy of Sciences.

[10]  E. Oki,et al.  Review of chemotherapeutic approaches for operable and inoperable esophageal squamous cell carcinoma. , 2016, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[11]  G. Taylor,et al.  PRIMA-1Met suppresses colorectal cancer independent of p53 by targeting MEK , 2016, Oncotarget.

[12]  M. Sánchez-Niño,et al.  MXRA5 is a TGF‐β1‐regulated human protein with anti‐inflammatory and anti‐fibrotic properties , 2016, Journal of cellular and molecular medicine.

[13]  I. Jang,et al.  Cordycepin promotes apoptosis by modulating the ERK-JNK signaling pathway via DUSP5 in renal cancer cells. , 2016, American journal of cancer research.

[14]  T. Somervaille,et al.  LSD1: biologic roles and therapeutic targeting , 2016, Epigenomics.

[15]  X. Chu,et al.  Irreversible LSD1 Inhibitors: Application of Tranylcypromine and Its Derivatives in Cancer Treatment. , 2016, Current topics in medicinal chemistry.

[16]  A. Porter,et al.  Deregulation of Rho GTPases in cancer , 2016, Small GTPases.

[17]  Jianbiao Zhou,et al.  PRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanisms , 2015, Oncotarget.

[18]  H. Yagi,et al.  Regulation of the Mechanism of TWIST1 Transcription by BHLHE40 and BHLHE41 in Cancer Cells , 2015, Molecular and Cellular Biology.

[19]  C. Buesa,et al.  Advances in the development of histone lysine demethylase inhibitors. , 2015, Current opinion in pharmacology.

[20]  F. Costa,et al.  Epigenomes as therapeutic targets. , 2015, Pharmacology & therapeutics.

[21]  P. Trojer,et al.  Targeting histone lysine methylation in cancer. , 2015, Pharmacology & therapeutics.

[22]  Takayoshi Suzuki,et al.  NCL1, a highly selective lysine-specific demethylase 1 inhibitor, suppresses prostate cancer without adverse effect , 2014, Oncotarget.

[23]  Sunil Sharma,et al.  Reversible inhibition of lysine specific demethylase 1 is a novel anti-tumor strategy for poorly differentiated endometrial carcinoma , 2014, BMC Cancer.

[24]  M. Takahashi,et al.  MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer , 2013, British Journal of Cancer.

[25]  M. Saha,et al.  PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa , 2013, Molecular Cancer Therapeutics.

[26]  M. Nagai,et al.  Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas , 2013, Virchows Archiv.

[27]  N. Mongan,et al.  The lysine specific demethylase‐1 (LSD1/KDM1A) regulates VEGF‐A expression in prostate cancer , 2013, Molecular oncology.

[28]  S. Orkin,et al.  Histone demethylase Lsd1 represses hematopoietic stem and progenitor cell signatures during blood cell maturation , 2013, eLife.

[29]  H. Matsubara,et al.  Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma , 2013, British Journal of Cancer.

[30]  Wen-guang Wu,et al.  Overexpression of lysine specific demethylase 1 predicts worse prognosis in primary hepatocellular carcinoma patients. , 2012, World journal of gastroenterology.

[31]  L. Yao,et al.  Identification of MXRA5 as a novel biomarker in colorectal cancer , 2012, Oncology letters.

[32]  H. Matsubara,et al.  miR-203 inhibits the migration and invasion of esophageal squamous cell carcinoma by regulating LASP1. , 2012, International journal of oncology.

[33]  G. Juliusson,et al.  Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  N. Seki,et al.  Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma. , 2012, International journal of oncology.

[35]  X. Hua,et al.  Exome sequencing identifies MXRA5 as a novel cancer gene frequently mutated in non-small cell lung carcinoma from Chinese patients. , 2012, Carcinogenesis.

[36]  T. Lv,et al.  Over-Expression of LSD1 Promotes Proliferation, Migration and Invasion in Non-Small Cell Lung Cancer , 2012, PloS one.

[37]  A. Ridley,et al.  Analysis of Rho GTPase expression in T-ALL identifies RhoU as a target for Notch involved in T-ALL cell migration , 2012, Oncogene.

[38]  闵先军,et al.  Oesophageal cancer , 2011 .

[39]  T. Gerds,et al.  PRIMA-1Met/APR-246 Induces Apoptosis and Tumor Growth Delay in Small Cell Lung Cancer Expressing Mutant p53 , 2011, Clinical Cancer Research.

[40]  Masayuki Kano,et al.  miR‐145, miR‐133a and miR‐133b: Tumor‐suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma , 2010, International journal of cancer.

[41]  Paola Chiarugi,et al.  Rac and Rho GTPases in cancer cell motility control , 2010, Cell Communication and Signaling.

[42]  Makoto Hasegawa,et al.  Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors. , 2010, Journal of medicinal chemistry.

[43]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[44]  R. Schüle,et al.  Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. , 2010, Carcinogenesis.

[45]  M. Cuesta,et al.  Systematic approach of postoperative gastric conduit complications after esophageal resection. , 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[46]  Aaron R. Quinlan,et al.  Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .

[47]  Makoto Hasegawa,et al.  Identification of cell-active lysine specific demethylase 1-selective inhibitors. , 2009, Journal of the American Chemical Society.

[48]  R. Weichselbaum,et al.  STAT1-dependent expression of energy metabolic pathways links tumour growth and radioresistance to the Warburg effect , 2009, BMC medicine.

[49]  C. Besch-Williford,et al.  PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. , 2009, International journal of oncology.

[50]  Zhong-ying Shen,et al.  Expression and prognostic significance of THBS1, Cyr61 and CTGF in esophageal squamous cell carcinoma , 2009, BMC Cancer.

[51]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[52]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[53]  Y. Ward,et al.  TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation , 2008, BMC Cancer.

[54]  A. Ridley,et al.  Rho GTPases in cancer cell biology , 2008, FEBS letters.

[55]  H. Matsubara,et al.  Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. , 2007, Oncology reports.

[56]  George Coukos,et al.  Tumor vascular proteins as biomarkers in ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  J. Fregnani,et al.  Down-regulation of PHLDA1 gene expression is associated with breast cancer progression , 2007, Breast Cancer Research and Treatment.

[58]  Jun Song,et al.  CEAS: cis-regulatory element annotation system , 2006, Nucleic Acids Res..

[59]  N. Seki,et al.  Histone Deacetylase Inhibitor FK228 Activates Tumor Suppressor Prdx1 with Apoptosis Induction in Esophageal Cancer Cells , 2005, Clinical Cancer Research.

[60]  Yang Shi,et al.  Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1 , 2004, Cell.

[61]  J. Takita,et al.  An immunohistochemical study of TIMP-3 expression in oesophageal squamous cell carcinoma , 2004, British Journal of Cancer.

[62]  E. Falk,et al.  TDAG51 Is Induced by Homocysteine, Promotes Detachment-mediated Programmed Cell Death, and Contributes to the Development of Atherosclerosis in Hyperhomocysteinemia* , 2003, Journal of Biological Chemistry.

[63]  R. Visse,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis: the Good, the Ba , 2022 .

[64]  J. Eriksson,et al.  Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors , 2003, Oncogene.

[65]  Judith P. Johnson,et al.  Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. , 2002, Cancer research.

[66]  V. Knäuper,et al.  Localization of the Death Domain of Tissue Inhibitor of Metalloproteinase-3 to the N Terminus , 2000, The Journal of Biological Chemistry.

[67]  M. Rosner,et al.  A Proline‐ and Glutamine‐Rich Protein Promotes Apoptosis in Neuronal Cells , 1999, Journal of neurochemistry.

[68]  A. Baker,et al.  Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3 , 1999, British Journal of Cancer.

[69]  V. Kähäri,et al.  Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. , 1998, Cancer research.

[70]  N. Colburn,et al.  TIMP-3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. , 1997, Cytokine.

[71]  C. Park,et al.  A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death. , 1996, Immunity.

[72]  S. Apte,et al.  The Gene Structure of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Its Inhibitory Activities Define the Distinct TIMP Gene Family (*) , 1995, The Journal of Biological Chemistry.

[73]  A. Mirsky,et al.  Structural Modifications of Histones and their Possible Role in the Regulation of RNA Synthesis. , 1964, Science.

[74]  H. Qin,et al.  Dual specificity phosphatase 5 is a novel prognostic indicator for patients with advanced colorectal cancer. , 2016, American journal of cancer research.

[75]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[76]  W. Kwapong,et al.  Matrix-remodeling associated 5 as a novel tissue biomarker predicts poor prognosis in non-small cell lung cancers. , 2015, Cancer biomarkers : section A of Disease markers.

[77]  Takayoshi Suzuki,et al.  Histone Demethylase LSD1 Inhibitors Prevent Cell Growth by Regulating Gene Expression in Esophageal Squamous Cell Carcinoma Cells , 2015, Annals of Surgical Oncology.

[78]  J. Luketich,et al.  Oesophageal carcinoma , 2013, The Lancet.

[79]  Peter D Siersema,et al.  Esophageal cancer. , 2008, Gastroenterology clinics of North America.

[80]  S. Franceschi,et al.  EPIDEMIOLOGY OF ESOPHAGEAL CANCER , 2013 .

[81]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.